Faes Farma, Invida sign commercialization agreement for bilastine

As per the agreement, Faes will be the exclusive supplier of the active Ingredient to Invida for the region and receive upfront and milestone payments.

Invida chief executive officer John Graham said, "The partnership will enable FAES to leverage on INVIDA’s established sales and marketing force of over 3.500 people, while allowing INVIDA to build upon FAES’s strong reputation and extensive experience."

The agreement allows Invida to cover the markets of China, Australia, Philippines, Vietnam, Thailand, Singapore, Taiwan and Malaysia.

The H1 anti-histamine drug is approved for the treatment of allergic rhinoconjunctivitis and urticaria in the European Union and in some other countries in Latin America.